Atom Investors LP - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
Atom Investors LP ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q3 2022$370,000
-53.2%
63,512
-52.1%
0.13%
-62.4%
Q2 2022$791,000
-9.8%
132,490
-29.4%
0.35%
-15.6%
Q1 2022$877,000
+209.9%
187,788
+64.6%
0.41%
+772.3%
Q4 2021$283,000114,1100.05%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 6,535,674$27,449,8319.21%
Bleichroeder LP 3,893,730$16,353,6663.49%
AIGH Capital Management LLC 2,100,000$8,820,0003.25%
Ally Bridge Group (NY) LLC 550,000$2,310,0003.03%
Ghost Tree Capital, LLC 2,000,000$8,400,0002.48%
Bain Capital Life Sciences Investors, LLC 4,702,996$19,7532.47%
Altium Capital Management LP 850,000$3,570,0001.98%
Parkman Healthcare Partners LLC 1,753,630$7,365,2461.60%
BVF INC/IL 8,813,021$37,014,6881.35%
Sio Capital Management, LLC 526,239$2,210,2041.09%
View complete list of CTI BIOPHARMA CORP shareholders